Quick Answer
ACADIA PHARMACEUTICALS INC reported R&D Expense of $328.80 million for fiscal year 2025.
ACADIA PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $328.80M | +8.4% |
| 2024 | $303.25M | -13.8% |
| 2023 | $351.62M | -2.8% |
| 2022 | $361.57M | +51.0% |
| 2021 | $239.41M | -25.0% |
| 2020 | $319.13M | +32.8% |
| 2019 | $240.38M | +28.4% |
| 2018 | $187.16M | +25.5% |
| 2017 | $149.19M | +50.3% |
| 2016 | $99.28M | +34.4% |
| 2015 | $73.87M | +21.9% |
| 2014 | $60.60M | +126.8% |
| 2013 | $26.72M | +42.2% |
| 2012 | $18.79M | +8.6% |
| 2011 | $17.31M | -15.9% |
| 2010 | $20.58M | -50.5% |
| 2009 | $41.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $87.83M | +31.9% | +12.7% |
| June 30, 2025 | $77.95M | +2.3% | -0.4% |
| March 31, 2025 | $78.27M | +31.1% | +17.5% |
| September 30, 2024 | $66.61M | -57.6% | -12.6% |
| June 30, 2024 | $76.23M | +29.7% | +27.7% |
| March 31, 2024 | $59.68M | -13.7% | -62.0% |
| September 30, 2023 | $156.96M | +93.0% | +167.1% |
| June 30, 2023 | $58.77M | -22.3% | -15.0% |
- ACADIA PHARMACEUTICALS INC showed an increase of +8.4% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, ACADIA PHARMACEUTICALS INC’s r&d expense has grown by 690.7% (from $41.59 million to $328.80 million).
- The most recent figure is from ACADIA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: